Biocytogen Announces FDA Approval of IND Application for Bispecific Antibody YH008
20 December 2022
Biocytogen Pharmaceuticals Co., Ltd. announced today that the US FDA has approved the Investigational New Drug application for a phase I study of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody. The IND application was completed by Eucure Biopharma, the wholly owned subsidiary of Biocytogen.
The study is an open-label, dose-escalation study (No. YH008101) that will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of YH008 monotherapy in patients with PD-(L)1-resistant advanced solid tumors or hematologic malignancies .
This announcement is official in its original source language. Translations are only intended as a reading aid and must be compared with the text in the source language, which is the only one legally valid.
Contacts
Biocytogen
Antibody drug assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
Source:businesswire.com